Use of Health Care Databases to Support Supplemental Indications of Approved Medications | Zendy

Michael Fralick | Zendy; Aaron S. Kesselheim | Zendy; Jerry Avorn | Zendy; Sebastian Schneeweiß | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Health Care Databases to Support Supplemental Indications of Approved Medications

Author(s) -

Michael Fralick,

Aaron S. Kesselheim,

Jerry Avorn,

Sebastian Schneeweiß

Publication year - 2017

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2017.3919

Subject(s) - medicine , telmisartan , ramipril , propensity score matching , randomized controlled trial , clinical trial , emergency medicine , medical prescription , stroke (engine) , intensive care medicine , database , pharmacology , mechanical engineering , computer science , blood pressure , engineering

Manufacturers of US Food and Drug Administration-approved prescription drugs often apply for additional indications based on randomized clinical trials. Real-world database analyses on a medication's use and outcomes in routine settings of care might help to inform decision making regarding such supplemental indications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research